Axogen Inc (AXGN)
Axogen Inc. is a healthcare company focused on technologies for peripheral nerve regeneration and repair. Through its subsidiaries, it develops and commercializes products used in surgical repair of peripheral nerve injuries, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. The company also provides the Avance Method, which is used to process donated human peripheral nerve tissue into its nerve graft product.
In addition to product development, Axogen is involved in peripheral nerve tissue recovery and acquisition, donor review and release, testing, debridement, packaging, and sterilization. Its customers include hospitals, surgery centers, and military hospitals, and it markets its products to surgeons such as plastic reconstructive, orthopedic, hand, and certain oral and maxillofacial specialists through independent in-country distributors. Axogen is headquartered in Alachua, Florida, and its common stock trades on NASDAQ under the ticker AXGN.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AXGN
|
$28.27
|
-36.5% Downside
|
Overvalued
|
$53.90
|
21.0% Upside
|
Undervalued
|
Good
|
0.0%
|
November 10, 2026
|
10.2x
|
10.4x
|
2.613 B
|
2.522 B
|
0.8%
|
98.1%
|
32.1
|
-25.6%
|
